Related Experiment Video

Updated: Mar 28, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

The Influence of OLR1 and PCSK9 Gene Polymorphisms on Ischemic Stroke: Evidence from a Meta-Analysis

Anthony Au1, Lyn R Griffiths2, Kian-Kai Cheng1,3

  • 1Institute of Bioproduct Development and Department of Bioprocess Engineering, Faculty of Chemical Engineering, Universiti Teknologi Malaysia, 81300 Johor, Malaysia.

Scientific Reports
|December 16, 2015
PubMed

Insights

Genetic variants in OLR1 and PCSK9 genes are linked to ischemic stroke risk. This meta-analysis found that OLR1 rs11053646 and PCSK9 rs505151 polymorphisms may increase susceptibility to ischemic stroke.

Area of Science:

  • Cardiovascular Genetics
  • Neurology
  • Molecular Biology

Background:

  • Atherosclerosis, cardiovascular disease, and ischemic stroke are linked to OLR1 and PCSK9 genes.
  • The association between OLR1 rs11053646 and PCSK9 rs505151 polymorphisms and ischemic stroke remains unclear.
  • Previous studies have yielded inconclusive results regarding these genetic associations.

Purpose of the Study:

  • To conduct the first meta-analysis clarifying the influence of OLR1 rs11053646 and PCSK9 rs505151 polymorphisms on ischemic stroke risk.
  • To pool data from existing studies to provide a more definitive conclusion.
  • To evaluate the contribution of these specific genetic variants to ischemic stroke susceptibility.

Main Methods:

  • Systematic retrieval of eligible case-control and cohort studies from multiple databases.
  • Extraction of demographic and genotyping data from selected studies.
  • Meta-analysis performed using RevMan 5.3 and Metafor R 3.2.1, calculating pooled odds ratios (ORs) and 95% confidence intervals (CIs) using fixed- and random-effect models.

Main Results:

  • Seven case-control studies involving 1897 cases and 2119 controls were analyzed.
  • The OLR1 rs11053646 polymorphism showed a significant association with ischemic stroke in dominant (OR=1.33, 95% CI: 1.11-1.58) and co-dominant models (OR=1.24, 95% CI: 1.02-1.51).
  • The PCSK9 rs505151 polymorphism exhibited an increased OR in the co-dominant model (OR=1.36, 95% CI: 1.01-1.58) among ischemic stroke patients.

Conclusions:

  • The variant allele of OLR1 rs11053646 (G>C) is associated with an increased risk of ischemic stroke.
  • The variant allele of PCSK9 rs505151 (A>G) may also contribute to the susceptibility of ischemic stroke.
  • These findings highlight the potential role of OLR1 and PCSK9 genetic variants in ischemic stroke pathogenesis.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
116
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
155
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
111
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K